Oral lactoferrin administration does not impact the diversity or composition of the infant gut microbiota in a Peruvian cohort

González L.; Paredes Sosa J.L.; Mosquito S.; Filio Y.; Romero P.E.; Ochoa T.J.; Tsukayama P. · Microbiology Spectrum (2023) · DOI: 10.1128/spectrum.00096-23

Resumen

Lactoferrin is a protein from breast milk involved in early-life microbiome assembly. It is believed to promote the growth of lactic acid-producing bacteria and inhibit pathogens by limiting iron availability and enabling an acidic environment in the gut. Previous reports suggest that oral administration of lactoferrin in neonates promotes the increase of gut microbiota diversity and the enrichment of beneficial microbes. However, its effect on infant gut microbiota over time has yet to be thoroughly studied to fully understand its potential as a prebiotic. Using 16s rRNA gene amplicon sequencing, we analyzed the gut microbiota composition of 60 toddlers at 12–18 months of age from Lima, Peru, who received daily oral administration of lactoferrin or placebo for 6 months since enrollment. Samples were analyzed at 0, 2, and 4 months after beginning treatment. Our results show that lactoferrin treatment does not increase gut microbiota diversity over time nor affect its bacterial composition compared to the placebo group. Copyright

Instituciones: Universidad Peruana Cayetano Heredia; Universidad Nacional Mayor de San Marcos